Prostate Cancer and Diseases of the Prostate - Center for Prostate Disease Research

> Integrating basic science and clinical research to develop promising detection techniques and treatments for prostate disease

The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Program, the Basic Science Research Program and the Multicenter National Prostate Cancer Database – and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.

To get started, find your selected interest below or use the blue navigation bar above.

CLINICIAN RESEARCHER PATIENT CPDR STAFF LISTING BY PROGRAM CPDR PARADIGM

> NEWS

CPDR Wins Best Paper Award

Thursday, January 17, 2008

The CPDR team won the 2007 Best Paper Award for Prostate Cancer and Prostatic Diseases sponsored by Astra Zeneca for its article on “Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase” (Kim et al., Prostate Cancer and Prostatic Diseases (2007) 10, 30-38).

The team, led by Dr. Shiv Srivastava, revealed the functional characteristics of a unique benign prostate tissue-derived immortalized epithelial cell line isolated from the tumor of an African American patient in the CPDR Cell Center by the research group of Dr. Johng S. Rhim.

Remarkably, this cell line exhibits the characteristics of a benign prostate epithelial cell, providing an exceptional opportunity to test cancer drugs on a benign prostate cell model. The rationale of these studies is that an anti-cancer drug should selectively eliminate cancer while having no effect on benign cells. The development of this and other cell culture models are the result of the continuous collaborative endeavors of CPDR’s integrated Clinical Research, Basic Science Research and Multicenter National Database Programs with the genitourinary pathologists of AFIP.

Full Article

Tri-service Prostate Patient Database

Current Nomogram Predicting 5- and 10-year Overall Survival for Prostate Cancer (CaP) Patients

In 2006, CPDR launched its latest nomogram predicting 5- and 10-year overall survival for prostate cancer (CaP) patients who have undergone radical prostatectomy followed by a PSA recurrence. This tool demonstrates the importance of PSA doubling time in predicting time to death among CaP patients treated surgically.

These results were presented in an Abstract at the second annual American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium, sponsored by ASCO, the Prostate Cancer Foundation, ASTRO, and the Society for Clinical Oncology (SUO).

Read Abstract

Go To Nomogram
(can only be viewed with IE 5.5 or higher)

> CPDR SATURDAY SEMINAR

Saturday, May 10, 2008
9:00 a.m. - 10:15 a.m.
10:15 a.m. – 11:00 a.m. Discussion & Q/A
CPDR, Rockville, MD

Angelo De Marzo, M.D., Ph.D.
Associate Professor of Pathology, Oncology and Urology
Associate Professor of Cancer Research Pathology
Johns Hopkins University School of Medicine

Presenting: "Patholobiology of Early
Prostate Cancer Formation"

Objectives:

Provide attendees an understanding of the role of key tumor suppressor genes, oncogenes and telomere shortening in prostate cancer formation; identify the potential role for inflammation and atrophy in prostate cancer formation; and the potential role of diet in prostate cancer formation.

CME Info: “Activity Period 1/12/08 - 1/11/09”

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Uniformed Services University of the Health Sciences (USUHS) and Center for Prostate Disease Research (CPDR). USUHS designates this educational activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

All planners, faculty, and others in a position to influence content will complete the disclosure process and report relevant financial relationships with any company or product that may be discussed as well as any planned discussion of non-FDA approved products or uses.

The Uniformed Health Services University (USUHS) employs appropriate mechanisms to resolve potential conflicts of interest and provide fair
and balanced education. Questions about specific strategies can be addressed to USUHS at continuingeducation@usuhs.mil.

Participants with special needs should contact the Center for Prostate Disease Research at (240) 453-8900 to discuss desired accommodation.

> UPDATES

WRAMC UsToo!

Dr. Steven Wilson, Radiation Oncologist, WRAMC Radiation Oncology Service, was our speaker for Wednesday, November 7, 2007.

His topic was “Radiation Therapy for Prostate Cancer: How New Technology Benefits Prostate Cancer Patients.” A summary of Dr. Wilson’s remarks is presented on page 7.

This newsletter is published quarterly. Don't miss a single issue.

February 2008, Volume 17, Number 1